Cerevel Therapeutics/CERE

$41.09

0.09%
-
1D1W1MYTD1YMAX

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Its pipeline with various clinical trials underway or planned, including three ongoing Phase III trials and an open-label extension trial for tavapadon in Parkinson's, two planned Phase II trials and a planned open-label extension trial for emraclidine in schizophrenia and an ongoing Phase II proof-of-concept trial with an open-label extension trial for darigabat in focal epilepsy.

Ticker

CERE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

N. Coles

Employees

334

Headquarters

Cambridge, United States

CERE Metrics

BasicAdvanced
$7.45B
Market cap
-
P/E ratio
-$2.66
EPS
1.50
Beta
-
Dividend rate

What the Analysts think about CERE

Analyst Ratings

Majority rating from 9 analysts.
Hold

Price Targets

Average projection from 10 analysts.
5.62% upside
High $45.00
Low $31.00
$41.09
Current price
$43.40
Average price target

CERE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-132.6M
37.69%
Profit margin
0%
-

CERE Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 27.75%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.67
-$0.63
-$0.61
-$0.76
-
Expected
-$0.67
-$0.65
-$0.63
-$0.59
-$0.59
Surprise
-0.65%
-2.86%
-3.51%
27.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Cerevel Therapeutics stock

Buy or sell Cerevel Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing